Relevant bibliographies by topics / Type 2 diabetes mellitus(Type 2 DM) Oral Hypoglycemic Agents (OHA) Insulin

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Type 2 diabetes mellitus(Type 2 DM) Oral Hypoglycemic Agents (OHA) Insulin'

Author: Grafiati

Published: 4 June 2025

Last updated: 15 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Type 2 diabetes mellitus(Type 2 DM) Oral Hypoglycemic Agents (OHA) Insulin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Type 2 diabetes mellitus(Type 2 DM) Oral Hypoglycemic Agents (OHA) Insulin"

Krishna, T. Sharmila, C. Suvarna Devi, U. Sreedhar, R. Viswa Kumar, and M. Prasad Naidu. "Estimation of glycemic control in patients with type 2 diabetes mellites with various forms of tuberculosis with dots." International Journal of Clinical Biochemistry and Research 8, no. 2 (2021): 120–23. http://dx.doi.org/10.18231/j.ijcbr.2021.026.

Full text

Abstract:

Since ancient times people are aware of the association between tuberculosis and diabetes mellitus. Patients with tuberculosis and diabetes experience worse clinical manifestations, increased risk of treatment failure, recurrence, and death. The present study was conducted to evaluate glycosylated hemoglobin (HbA1c) and blood glucose levels, in patients with Type - 2 diabetes mellitus with various forms of tuberculosis who are on RNTCP DOTS and antidiabetic regimens. The study subjects included Type-2 diabetes mellitus with tuberculosis who are registered under RNTCP DOTS, in Dept of Pulmonolo

APA, Harvard, Vancouver, ISO, and other styles

K.C., Indu. "Causes of Hypoglycemia in Hospitalized Diabetic Patients Referred to Endocrine Department of a Tertiary Level Hospital of India." Medical Journal of Shree Birendra Hospital 15, no. 1 (2016): 26–31. http://dx.doi.org/10.3126/mjsbh.v15i1.15018.

Full text

Abstract:

Introduction: Diabetes mellitus (DM) results from relative deficiency or reduced effectiveness of endogenous insulin leading to both micro-vascular and macro-vascular complications. Treatment goal is intensive therapy as early as possible in patients with both type-1 and type-2 diabetes to bring the HbA1c to less than 7%. Occurrence of hypoglycemia in a diabetic patient is a common side effect of treatment. This study was aimed to find the causes of Hypoglycemia in diabetes patients. Methods: It was hospital based cross-sectional observational study on admitted diabetes patients with other co-

APA, Harvard, Vancouver, ISO, and other styles

Rajaragupathy, Sujatha, Deepika Ponnusamy, Dhanalakshmi Balasundararaj, Sandhiya Venkatesan, and Jayagowri Karthikeyan. "Serum megalin levels in type-2 diabetes mellitus with and without cardiovascular disease." Journal of Family Medicine and Primary Care 13, no. 11 (2024): 5240–43. http://dx.doi.org/10.4103/jfmpc.jfmpc_989_24.

Full text

Abstract:

ABSTRACT Background: Low-density lipoprotein receptor-related protein-2 (LRP2), also called megalin, is a multi-ligand receptor of the LDL receptor gene family mediating reabsorption of ligands like Apo-A1. Type 2 diabetes mellitus (T2DM) may possibly disrupt megalin functions as it is found to be regulated by insulin. This might cause cardiovascular complications due to derangement in lipoprotein metabolism. The current study was carried out to assess the serum megalin levels among T2DM individuals with cardiovascular complications in the Indian population. Methods: This was a cross-sectional

APA, Harvard, Vancouver, ISO, and other styles

F. S, Mohammed, and Ansam N. Al-Hassani. "Clinical efficacy of Diabecon in treatment of type 2 diabetes mellitus, in newly diagnosed diabetic patients and in those on drug treatment (Glibenclamide and Metformin) in Erbil Governarate-Kurdistan Region/ Iraq." Al Mustansiriyah Journal of Pharmaceutical Sciences 13, no. 1 (2013): 44–51. http://dx.doi.org/10.32947/ajps.v13i1.177.

Full text

Abstract:

Various herbs have been found beneficial in the management of type 2 diabetes and are gaining considerable recognition in the management of type 2diabetes worldwide. The present study was planned to evaluate the clinical efficacy of Diabecon (Herbal formulation) as a mono therapy and also as an adjunct with other oral hypoglycemic agents, in the management of type 2 DM. A total of 80 patients of either sex, between 30-68 years of age, in whom the diagnosis of type 2 diabetes was confirmed, and who were willing to give informed consent were included in the study.All enrolled patients were categ

APA, Harvard, Vancouver, ISO, and other styles

Gul, Nadia, Inayat Ur Rehman, Yasar shah, et al. "Comparing dual oral agents plus insulin vs. Triple oral agents in uncontrolled type II diabetes: A pilot study." PLOS ONE 19, no. 11 (2024): e0311435. http://dx.doi.org/10.1371/journal.pone.0311435.

Full text

Abstract:

Introduction Type II Diabetes mellitus (T2DM) patients often do not achieve glycemic control with oral hypoglycemic agents (OHAs). There are two main approaches to address this challenge: transitioning to a triple OHA regimen, or adding Insulin to the existing dual OHA regimen. Aim This study aimed to compare the efficacy of adding Insulin to dual OHAs (Sitagliptin + Metformin) against adding a third OHA to Sitagliptin + Metformin in achieving glycemic control among patients with uncontrolled T2DM. Method A pre-post study was conducted between 21 September 2023 and 21 December 2023 at Services

APA, Harvard, Vancouver, ISO, and other styles

Antsiferov, M. B. "Initiation of insulin therapy for type 2 diabetes mellitus." Problems of Endocrinology 55, no. 5 (2009): 3–5. http://dx.doi.org/10.14341/probl20095553-5.

Full text

Abstract:

This program is designed to identify patients in whom diabetes mellitus resists therapy with oral hypoglycemic agents (OHA) and basal insulin administration is needed to maintain the HbA1c at the desired level below 7. Data from 2895 patients (2034 women and 851 men) were available for analysis. Only 2.6% of the patients had the glycated hemoglobin (HbA1c) level within the normal values prior to the onset of therapy. The remaining ones had decompensated diabetes mellitus that required supplementation of regular OHA therapy with Lantus insulin. Characteristics of carbohydrate metabolism signifi

APA, Harvard, Vancouver, ISO, and other styles

Umesh, Teltumbade. "Assessment of Control of Cardiovascular Risk Factorsin Type-2 Diabetes." International Journal of Pharmaceutical and Clinical Research 14, no. 12 (2022): 735–40. https://doi.org/10.5281/zenodo.13881504.

Full text

Abstract:

Introduction: Diabetic patients are at increased risk for coronary heart disease and experience increased morbidity and mortality from coronary heart disease compared to their non-diabetic counterparts. he specific factors that can make this expanded hazard include obesity, hyperglycemia, high blood pressure (BP), insulin resistance, and dyslipidemia. When patients are physically inactive or smokers and have at least one cardiometabolic risk factor, this markedly increases the cardiometabolic risk. Also, clustering of these risk factors can markedly increase the risk of c

APA, Harvard, Vancouver, ISO, and other styles

Azhar Memon, Shomail Saeed Siddiqui, Muhammad Atif Ata, Kashif Rasheed Shaikh, Umair Ali Soomro, and Shumaila Shaikh. "Silymarin improves glycemic control through reduction of insulin resistance in newly diagnosed patients of type 2 diabetes mellitus." Professional Medical Journal 29, no. 03 (2022): 362–66. http://dx.doi.org/10.29309/tpmj/2022.29.03.6477.

Full text

Abstract:

Objective: To study, analyse and compare the effects of Silymarin on glycemic control and insulin resistance in newly diagnosed type 2 diaebtes mellitus (T2DM) subjects. Study Design: Observational study. Setting: Suleman Roshan Medical College Hospital. Period: March 2019 to February 2020. Material & Methods: A sample of 200 newly diagnosed cases of T2DM were recruited accroding to inclusion criteria selected by non-probability convenient sampling. Subjects were divided into 2 groups; OHA- oral hypoglycemia agent and OHA+ Sillymarin (200 mg). Baseline fasting (FBG) and random blood glucos

APA, Harvard, Vancouver, ISO, and other styles

Syed, Areefulla Hussainy* Mariyam Hyder Nameera Hyder Mariyam Firdous Sana Sultana and Dr Rafiya Sultana. "A PROSPECTIVE OBSERVATIONAL STUDY IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS AT TERTIARY CARE TEACHING HOSPITAL." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 05, no. 07 (2018): 6406–29. https://doi.org/10.5281/zenodo.1311187.

Full text

Abstract:

AIM & OBJECTIVE: A prospective observational study in the treatment of Type 2 Diabetes Mellitus at tertiary care teaching hospital. METHODOLOGY: A Prospective observational study carried out in the Department of general medicine in Osmania General Hospital, a tertiary care teaching hospital for a period of 6months. All the patients of either sex attending General medicine department with established type 2 Diabetes Mellitus were included in the study. In-patients already diagnosed of Type 2 diabetes mellitus and are on treatm

APA, Harvard, Vancouver, ISO, and other styles

Kaur, Pardeep, Munish Kumar, Jyoti Parkash, and D. N. Prasad. "Oral hypoglycemic drugs: An overview." Journal of Drug Delivery and Therapeutics 9, no. 3-s (2019): 770–77. http://dx.doi.org/10.22270/jddt.v9i3-s.2815.

Full text

Abstract:

The aim of this study was to evaluate safety and efficacy of oral hypoglycemic agents in obese Type-2 diabetic patients. The objectives are to compare fasting and postprandial blood sugar (PPBS) levels, to compare body mass index in all the groups and to identify glycosylated hemoglobin levels and adverse drug reaction in all the groups. Diabetes mellitus is one of the world’s major diseases. It currently affects an estimated143 million people worldwide and the number is growing rapidly. In the India, about 1-5% population suffer from diabetes or related complication. So there is need to cure

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Type 2 diabetes mellitus(Type 2 DM) Oral Hypoglycemic Agents (OHA) Insulin"

"Combined therapy with oral hypoglycaemic agents compared to insulin therapy alone in Hong Kong Chinese patients with non-insulin dependent diabetes mellitus." 1997. http://library.cuhk.edu.hk/record=b5889155.

Full text

Abstract:

by Lynn Wah Wong Tsang. Consent form in Chinese. Thesis (M.Phil.)--Chinese University of Hong Kong, 1997. Includes bibliographical references (leaves 127-145). Declaration --- p.i Acknowledgments --- p.ii Table of Contents --- p.iii List of Tables --- p.vii List of Figures --- p.x List of Appendix --- p.xi Chapter CHAPTER1 --- INTRODUCTION Chapter 1.1 --- General Introduction --- p.2 Chapter 1.2 --- Literature Review --- p.6 Chapter 1.2.1 --- Classifications of Diabetes Mellitus --- p.6 Chapter 1.2.2 --- Diagnostic Criteria of Diabetes Mellitu

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Type 2 diabetes mellitus(Type 2 DM) Oral Hypoglycemic Agents (OHA) Insulin"

J, Ahr H., Kuhlmann J, and Puls Walter, eds. Oral antidiabetics. Springer, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Type 2 diabetes mellitus(Type 2 DM) Oral Hypoglycemic Agents (OHA) Insulin"

Nelli, Giribabu, Naguib Salleh, and Gowri Gopa Kumar. "Anti-Diabetic Phytochemicals and Their Mode of Action." In Pharmacological Benefits of Natural Agents. IGI Global, 2023. http://dx.doi.org/10.4018/978-1-6684-6737-4.ch009.

Full text

Abstract:

The number of people diagnosed with diabetes mellitus (DM) has risen considerably in recent decades. Diabetes type 1 and 2 are the most frequent types. Type 2 diabetes accounts for 90% of all DM cases globally, making it a 21st-century epidemic. Meanwhile, the side effects and resistance development of routinely used synthetic oral hypoglycemic medications have side effects. It's a need for a safe and less costly substitute. This chapter looks at the anti-diabetic properties of several bioactive compounds derived from plants, such as boldine, bergenin, abietic acid, and myristic acid. This chapter examines the active compounds that can be obtained from plants and their potential use in the treatment of diabetes mellitus, as well as the molecular mechanisms underlying their actions in ameliorating diabetes complications. Consequently, creating novel anti-diabetic oral medications requires a detailed understanding of the mechanisms of action of these phytochemicals.

APA, Harvard, Vancouver, ISO, and other styles

Valdés Rubio, Enrique. "Impact of the Use of Metformin in the Prevention of Gestational Diabetes Mellitus in the High-Risk Population: An Article Review." In Glucose and Insulin Homeostasis. IntechOpen, 2024. http://dx.doi.org/10.5772/intechopen.1006121.

Full text

Abstract:

Gestational diabetes mellitus (GDM) is a condition characterized by a carbohydrate metabolism disorder of variable severity. The onset or first detection occurs during pregnancy. Its prevalence has increased dramatically in the last 10 years. Etiological factors that make these pregnant women a population at a high risk of developing GDM include maternal obesity, increase in maternal age, family history of diabetes mellitus, polycystic ovary (PCOS) and pregestational insulin resistance (PIR). The impact of metformin (MET), a second-generation insulin-sensitizing biguanide, on the prevention treatment of GDM has been studied with contradictory results. Through an article review of the literature, this chapter seeks to determine the safety and effectiveness of MET in preventing the development of GDM in patients with PIR in addition to evaluating the impact of oral hypoglycemic agents in the treatment of GDM and type 2 DM.

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Type 2 diabetes mellitus(Type 2 DM) Oral Hypoglycemic Agents (OHA) Insulin"

LV, WEN-TAO, QIU-MEI ZHANG, and XIANG-WEN MENG. "EFFECT OF SGLT-2 INHIBITOR ON BONE TURNOVER IN OVERWEIGHT AND OBESE PATIENTS WITH TYPE 2 DIABETES." In 2021 International Conference on Education, Humanity and Language, Art. Destech Publications, Inc., 2021. http://dx.doi.org/10.12783/dtssehs/ehla2021/35720.

Full text

Abstract:

To investigate the effect of sodium glucose cotransporter 2 inhibitor (SGLT-2I) on bone turnover markers in overweight and obese patients with type 2 diabetes mellitus. Methods: according to the criteria of selection and exclusion, 42 patients with overweight and obese type 2 diabetes (BMI≥25kg/m2) were selected from October 2019 to May 2020. The patients were randomly divided into experimental group and control group, there were 18 cases in the experimental group and 24 cases in the control group. The experimental group was treated with SGLT-2I, and other oral hypoglycemic agents (or insulin)

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!